From the Department of Ophthalmology, University of California, San Francisco, San Francisco, California (S.C. Schallhorn, J.M. Schallhorn); Optical Express, Glasgow, United Kingdom (S.C. Schallhorn, Hettinger, Hannan, Venter, Teenan); Carl Zeiss Meditec, Inc., Dublin, California (S.C. Schallhorn); F.I. Proctor Foundation, University of California, San Francisco, San Francisco, California (J.M. Schallhorn).

Corresponding author: Steven C. Schallhorn, MD, 11730 Caminito Prenticia, San Diego, CA 92131. Email: [email protected].

Disclosures: S.C. Schallhorn is a chief medical officer for Carl Zeiss Meditec AG and a chairman of medical advisory board for Optical Express. S.J. Hannan, J.A. Venter, and D. Teenan are employees of Optical Express. J.M. Schallhorn received personal fees from Carl Zeiss Meditec AG, Allergan, Inc., and Forsight V6 and has a financial interest in Journey 1, Neurotrigger, and Novus Vision.

First author:Steven C. Schallhorn, MDDepartment of Ophthalmology, University of California, San Francisco, San Francisco, California